Back

Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry

27 August 2023 (09:42 - 10:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes Thrombosis, Platelets, and Coagulation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Anton Haakansson

Skane University Hospital, Lund (Sweden)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
Professor G. Montalescot (Paris, FR)
Slides Video
Presentation thumbnail
Incidence and pattern of repeat coronary revascularizations in patients with acute coronary syndromes treated with ticagrelor or prasugrel
Doctor A. Aytekin (Munich, DE)
Abstract Slides Video
Presentation thumbnail
SGLT-2 inhibitors are associated with lower rates of mortality following myocardial infarction in patients with type 2 diabetes - A SWEDEHEART observational study
Doctor H. Rosen (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Current concepts of treatment for left ventricular thrombus: A sys-tematic meta-analysis comparing direct oral anticoagulants versus vitamin K-antagonists
Mr T. Seiler (Bern, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 09:42 CET
You may be interested in
thumbnail
Congress Presentation
Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro
thumbnail
Congress Presentation
Discussant review - DUAL-ACS
thumbnail
Congress Session
HOT LINE 6

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources